nach oben

Sleep and Breathing

Erschienen in:

07.08.2023 | Sleep Breathing Physiology and Disorders • Review

Effects of obstructive sleep apnea on myocardial injury and dysfunction: a review focused on the molecular mechanisms of intermittent hypoxia

verfasst von: Wen Liu, Qing Zhu, Xinxin Li, Yonghuai Wang, Cuiting Zhao, Chunyan Ma

Erschienen in: Sleep and Breathing | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Obstructive sleep apnea (OSA) is characterized by intermittent hypoxia (IH) and is strongly associated with adverse cardiovascular outcomes. Myocardial injury and dysfunction have been commonly observed in clinical practice, particularly in patients with severe OSA. However, the underlying mechanisms remain obscure. In this review, we summarized the molecular mechanisms by which IH impact on myocardial injury and dysfunction. In brief, IH-induced cardiomyocyte death proceeds through the regulation of multiple biological processes, including differentially expressed transcription factors, alternative epigenetic programs, and altered post-translational modification. Besides cell death, various cardiomyocyte injuries, such as endoplasmic reticulum stress, occurs with IH. In addition to the direct effects on cardiomyocytes, IH has been found to deteriorate myocardial blood and energy supply by affecting the microvascular structure and disrupting glucose and lipid metabolism. For better diagnosis and treatment of OSA, further studies on the molecular mechanisms of IH-induced myocardial injury and dysfunction are essential.

Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG (2017) Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 13:479–504. https://doi.org/10.5664/jcsm.6506CrossRefPubMedPubMedCentral

Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pepin JL et al (2019) Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med 7:687–698. https://doi.org/10.1016/S2213-2600(19)30198-5CrossRefPubMedPubMedCentral

Heilbrunn E, Ssentongo P, Chinchilli VM, Ssentongo AE (2020) Sudden death in individuals with obstructive sleep apnoea: protocol for a systematic review and meta-analysis. BMJ Open 10:e039774. https://doi.org/10.1136/bmjopen-2020-039774CrossRefPubMedPubMedCentral

Yeghiazarians, Y.; Jneid, H.; Tietjens, J.R.; Redline, S.; Brown, D.L.; El-Sherif, N.; Mehra, R.; Bozkurt, B.; Ndumele, C.E.; Somers, V.K. (2021) Obstructive Sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 144:e56-e67. i:https://doi.org/10.1161/CIR.0000000000000988

Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, Malhotra A, Martinez-Garcia MA, Mehra R, Pack AI et al (2017) Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol 69:841–858. https://doi.org/10.1016/j.jacc.2016.11.069CrossRefPubMedPubMedCentral

Freitas LS, Silveira AC, Martins FC, Costa-Hong V, Lebkuchen A, Cardozo KHM, Bernardes FM, Bortolotto LA, Lorenzi-Filho G, Oliveira EM et al (2020) Severe obstructive sleep apnea is associated with circulating microRNAs related to heart failure, myocardial ischemia, and cancer proliferation. Sleep Breath 24:1463–1472. https://doi.org/10.1007/s11325-019-02003-1CrossRefPubMed

Zietzer A, Breitruck N, Dusing P, Bohle S, Klussmann JP, Al-Kassou B, Goody PR, Hosen MR, Nickenig G, Nachtsheim L et al (2022) The lncRNA MRPL20-AS1 is associated with severe OSAS and downregulated upon hypoxic injury of endothelial cells. Int J Cardiol. https://doi.org/10.1016/j.ijcard.2022.08.035

Querejeta Roca G, Redline S, Punjabi N, Claggett B, Ballantyne CM, Solomon SD, Shah AM (2013) Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med 188:1460–1465. https://doi.org/10.1164/rccm.201309-1572OCCrossRefPubMed

Einvik G, Rosjo H, Randby A, Namtvedt SK, Hrubos-Strom H, Brynildsen J, Somers VK, Omland T (2014) Severity of obstructive sleep apnea is associated with cardiac troponin I concentrations in a community-based sample: data from the Akershus Sleep Apnea Project. Sleep 37(1111-1116):1116A–1116B. https://doi.org/10.5665/sleep.3772CrossRef

10.

Levy P, Naughton MT, Tamisier R, Cowie MR, Bradley TD (2022) Sleep apnoea and heart failure. Eur Respir J 59. https://doi.org/10.1183/13993003.01640-2021

11.

D'Andrea A, Canora A, Sperlongano S, Galati D, Zanotta S, Polistina GE, Nicoletta C, Ghinassi G, Galderisi M, Zamparelli AS et al (2020) Subclinical impairment of dynamic left ventricular systolic and diastolic function in patients with obstructive sleep apnea and preserved left ventricular ejection fraction. BMC Pulm Med 20:76. https://doi.org/10.1186/s12890-020-1099-9CrossRefPubMedPubMedCentral

12.

Raut S, Gupta G, Narang R, Ray A, Pandey RM, Malhotra A, Sinha S (2021) The impact of obstructive sleep apnoea severity on cardiac structure and injury. Sleep Med 77:58–65. https://doi.org/10.1016/j.sleep.2020.10.024CrossRefPubMed

13.

Labarca G, Dreyse J, Drake L, Jorquera J, Barbe F (2020) Efficacy of continuous positive airway pressure (CPAP) in the prevention of cardiovascular events in patients with obstructive sleep apnea: Systematic review and meta-analysis. Sleep Med Rev 52:101312. https://doi.org/10.1016/j.smrv.2020.101312CrossRefPubMed

14.

McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z et al (2016) CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 375:919–931. https://doi.org/10.1056/NEJMoa1606599CrossRefPubMed

15.

Kim D, Shim CY, Cho YJ, Park S, Lee CJ, Park JH, Cho HJ, Ha JW, Hong GR (2019) Continuous positive airway pressure therapy restores cardiac mechanical function in patients with severe obstructive sleep apnea: a randomized, sham-controlled study. J Am Soc Echocardiogr 32:826–835. https://doi.org/10.1016/j.echo.2019.03.020CrossRefPubMed

16.

Giampa SQC, Furlan SF, Freitas LS, Macedo TA, Lebkuchen A, Cardozo KHM, Carvalho VM, Martins FC, Azam IFB, Costa-Hong V et al (2022) Effects of CPAP on metabolic syndrome in patients with OSA: a randomized trial. Chest 161:1370–1381. https://doi.org/10.1016/j.chest.2021.12.669CrossRefPubMed

17.

Brozyna-Tkaczyk K, Myslinski W, Mosiewicz J (2021) The assessment of endothelial dysfunction among OSA patients after CPAP treatment. Medicina (Kaunas) 57. https://doi.org/10.3390/medicina57040310

18.

Chen TY, Liu CT, Chung CH, Hung SL, Chien WC, Chen JH (2021) Bariatric surgery may provide better protection than uvulopalatopharyngoplasty against major adverse cardiovascular events in obese patients with obstructive sleep apnea. Surg Obes Relat Dis 17:780–791. https://doi.org/10.1016/j.soard.2020.11.018CrossRefPubMed

19.

Wu J, Stefaniak J, Hafner C, Schramel JP, Kaun C, Wojta J, Ullrich R, Tretter VE, Markstaller K, Klein KU (2016) Intermittent hypoxia causes inflammation and injury to human adult cardiac myocytes. Anesth Analg 122:373–380. https://doi.org/10.1213/ANE.0000000000001048CrossRefPubMed

20.

Zhu D, Kang W, Zhang S, Qiao X, Liu J, Liu C, Lu H (2020) Effect of mandibular advancement device treatment on HIF-1alpha, EPO and VEGF in the myocardium of obstructive sleep apnea-hypopnea syndrome rabbits. Sci Rep 10:13261. https://doi.org/10.1038/s41598-020-70238-0CrossRefPubMedPubMedCentral

21.

Moulin S, Thomas A, Arnaud C, Arzt M, Wagner S, Maier LS, Pepin JL, Godin-Ribuot D, Gaucher J, Belaidi E (2020) Cooperation between hypoxia-inducible factor 1alpha and activating transcription factor 4 in sleep apnea-mediated myocardial injury. Can J Cardiol 36:936–940. https://doi.org/10.1016/j.cjca.2020.04.002CrossRefPubMed

22.

Prabhakar NR, Kumar GK, Nanduri J, Semenza GL (2007) ROS signaling in systemic and cellular responses to chronic intermittent hypoxia. Antioxid Redox Signal 9:1397–1403. https://doi.org/10.1089/ars.2007.1732CrossRefPubMed

23.

Semenza GL (2009) Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda) 24:97–106. https://doi.org/10.1152/physiol.00045.2008CrossRefPubMed

24.

Yuan G, Nanduri J, Khan S, Semenza GL, Prabhakar NR (2008) Induction of HIF-1alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J Cell Physiol 217:674–685. https://doi.org/10.1002/jcp.21537CrossRefPubMedPubMedCentral

25.

Cataldi A, Bianchi G, Rapino C, Sabatini N, Centurione L, Di Giulio C, Bosco D, Antonucci A (2004) Molecular and morphological modifications occurring in rat heart exposed to intermittent hypoxia: role for protein kinase C alpha. Exp Gerontol 39:395–405. https://doi.org/10.1016/j.exger.2003.11.010CrossRefPubMed

26.

Moulin S, Arnaud C, Bouyon S, Pepin JL, Godin-Ribuot D, Belaidi E (2020) Curcumin prevents chronic intermittent hypoxia-induced myocardial injury. Ther Adv Chronic Dis 11:2040622320922104. https://doi.org/10.1177/2040622320922104CrossRefPubMedPubMedCentral

27.

Bianchi G, Di Giulio C, Rapino C, Rapino M, Antonucci A, Cataldi A (2006) p53 and p66 proteins compete for hypoxia-inducible factor 1 alpha stabilization in young and old rat hearts exposed to intermittent hypoxia. Gerontology 52:17–23. https://doi.org/10.1159/000089821CrossRefPubMed

28.

Holscher M, Schafer K, Krull S, Farhat K, Hesse A, Silter M, Lin Y, Pichler BJ, Thistlethwaite P, El-Armouche A et al (2012) Unfavourable consequences of chronic cardiac HIF-1alpha stabilization. Cardiovasc Res 94:77–86. https://doi.org/10.1093/cvr/cvs014CrossRefPubMed

29.

Hu Y, Lu H, Li H, Ge J (2022) Molecular basis and clinical implications of HIFs in cardiovascular diseases. Trends Mol Med 28:916–938. https://doi.org/10.1016/j.molmed.2022.09.004CrossRefPubMed

30.

Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF (2006) Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 343:591–596. https://doi.org/10.1016/j.bbrc.2006.03.015CrossRefPubMed

31.

Goldbart AD, Gannot M, Haddad H, Gopas J (2020) Nuclear factor kappa B activation in cardiomyocytes by serum of children with obstructive sleep apnea syndrome. Sci Rep 10:22115. https://doi.org/10.1038/s41598-020-79187-0CrossRefPubMedPubMedCentral

32.

Wang ZH, Zhu D, Xie S, Deng Y, Pan Y, Ren J, Liu HG (2017) Inhibition of rho-kinase attenuates left ventricular remodeling caused by chronic intermittent hypoxia in rats via suppressing myocardial inflammation and apoptosis. J Cardiovasc Pharmacol 70:102–109. https://doi.org/10.1097/FJC.0000000000000496CrossRefPubMed

33.

Nakagawa T, Furukawa Y, Hayashi T, Nomura A, Yokoe S, Moriwaki K, Kato R, Ijiri Y, Yamaguchi T, Izumi Y et al (2019) Augmented O-GlcNAcylation attenuates intermittent hypoxia-induced cardiac remodeling through the suppression of NFAT and NF-kappaB activities in mice. Hypertens Res 42:1858–1871. https://doi.org/10.1038/s41440-019-0311-xCrossRefPubMed

34.

Han Q, Yeung SC, Ip MS, Mak JC (2014) Cellular mechanisms in intermittent hypoxia-induced cardiac damage in vivo. J Physiol Biochem 70:201–213. https://doi.org/10.1007/s13105-013-0294-zCrossRefPubMed

35.

Han Q, Li G, Ip MS, Zhang Y, Zhen Z, Mak JC, Zhang N (2018) Haemin attenuates intermittent hypoxia-induced cardiac injury via inhibiting mitochondrial fission. J Cell Mol Med 22:2717–2726. https://doi.org/10.1111/jcmm.13560CrossRefPubMedPubMedCentral

36.

Wang Q, Wang Y, Zhang J, Pan S, Liu S (2022) Silencing MR-1 protects against myocardial injury induced by chronic intermittent hypoxia by targeting Nrf2 through antioxidant stress and anti-inflammation pathways. J Healthc Eng 2022:3471447. https://doi.org/10.1155/2022/3471447CrossRefPubMedPubMedCentral

37.

Lin G, Huang J, Chen Q, Chen L, Feng D, Zhang S, Huang X, Huang Y, Lin Q (2019) miR-146a-5p mediates intermittent hypoxia-induced injury in H9c2 cells by targeting XIAP. Oxid Med Cell Longev 2019:6581217. https://doi.org/10.1155/2019/6581217CrossRefPubMedPubMedCentral

38.

Chen Q, Lin G, Chen Y, Li C, Wu L, Hu X, Lin Q (2021) miR-3574 ameliorates intermittent hypoxia-induced cardiomyocyte injury through inhibiting Axin1. Aging (Albany NY) 13:8068–8077. https://doi.org/10.18632/aging.202480CrossRefPubMed

39.

Chen Q, Lin G, Lin L, Huang J, Chen L, Lian N, Chen M, Zeng A, Lin Q (2022) LncRNA XR_596701 protects H9c2 cells against intermittent hypoxia-induced injury through regulation of the miR-344b-5p/FAIM3 axis. Cell Death Discov 8:42. https://doi.org/10.1038/s41420-022-00834-8CrossRefPubMedPubMedCentral

40.

Chen Q, Guo D, Lin G, Chen M, Huang J, Lin Q (2022) LncRNA XR_595552 inhibition alleviates intermittent hypoxia-induced cardiomyocyte damage via activating the PI3K/AKT pathway. Sleep Breath. https://doi.org/10.1007/s11325-022-02584-4

41.

Lai S, Chen L, Zhan P, Lin G, Lin H, Huang H, Chen Q (2021) Circular RNA expression profiles and bioinformatic analysis in mouse models of obstructive sleep apnea-induced cardiac injury: novel insights into pathogenesis. Front Cell Dev Biol 9:767283. https://doi.org/10.3389/fcell.2021.767283CrossRefPubMedPubMedCentral

42.

Kumar GK, Prabhakar NR (2008) Post-translational modification of proteins during intermittent hypoxia. Respir Physiol Neurobiol 164:272–276. https://doi.org/10.1016/j.resp.2008.05.017CrossRefPubMedPubMedCentral

43.

Wu Y, Wang H, Brautigan DL, Liu Z (2007) Activation of glycogen synthase in myocardium induced by intermittent hypoxia is much lower in fasted than in fed rats. Am J Physiol Endocrinol Metab 292:E469–E475. https://doi.org/10.1152/ajpendo.00486.2006CrossRefPubMed

44.

Beguin PC, Belaidi E, Godin-Ribuot D, Levy P, Ribuot C (2007) Intermittent hypoxia-induced delayed cardioprotection is mediated by PKC and triggered by p38 MAP kinase and Erk1/2. J Mol Cell Cardiol 42:343–351. https://doi.org/10.1016/j.yjmcc.2006.11.008CrossRefPubMed

45.

Xie Y, Zhu Y, Zhu WZ, Chen L, Zhou ZN, Yuan WJ, Yang HT (2005) Role of dual-site phospholamban phosphorylation in intermittent hypoxia-induced cardioprotection against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 288:H2594–H2602. https://doi.org/10.1152/ajpheart.00926.2004CrossRefPubMed

46.

Bai X, Yang H, Pu J, Zhao Y, Jin Y, Yu Q (2021) MKRN1 ubiquitylates p21 to protect against intermittent hypoxia-induced myocardial apoptosis. Oxid Med Cell Longev 2021:9360339. https://doi.org/10.1155/2021/9360339CrossRefPubMedPubMedCentral

47.

Zhou S, Yin X, Zheng Y, Miao X, Feng W, Cai J, Cai L (2014) Metallothionein prevents intermittent hypoxia-induced cardiac endoplasmic reticulum stress and cell death likely via activation of Akt signaling pathway in mice. Toxicol Lett 227:113–123. https://doi.org/10.1016/j.toxlet.2014.03.011CrossRefPubMed

48.

Zhou, X.; Tang, S.; Hu, K.; Zhang, Z.; Liu, P.; Luo, Y.; Kang, J.; Xu, L. (2018) DL-Propargylglycine protects against myocardial injury induced by chronic intermittent hypoxia through inhibition of endoplasmic reticulum stress. Sleep Breath 22:853-863. i:https://doi.org/10.1007/s11325-018-1656-0

49.

Zhang Q, Zhang X, Ding N, Ge L, Dong Y, He C, Ding W (2020) Globular adiponectin alleviates chronic intermittent hypoxia-induced H9C2 cardiomyocytes apoptosis via ER-phagy induction. Cell Cycle 19:3140–3153. https://doi.org/10.1080/15384101.2020.1836438CrossRefPubMedPubMedCentral

50.

Sun ZM, Guan P, Luo LF, Qin LY, Wang N, Zhao YS, Ji ES (2020) Resveratrol protects against CIH-induced myocardial injury by targeting Nrf2 and blocking NLRP3 inflammasome activation. Life Sci 245:117362. https://doi.org/10.1016/j.lfs.2020.117362CrossRefPubMed

51.

Tao L, Wang L, Yang X, Jiang X, Hua F (2019) Recombinant human glucagon-like peptide-1 protects against chronic intermittent hypoxia by improving myocardial energy metabolism and mitochondrial biogenesis. Mol Cell Endocrinol 481:95–103. https://doi.org/10.1016/j.mce.2018.11.015CrossRefPubMed

52.

Song JX, Zhao YS, Zhen YQ, Yang XY, Chen Q, An JR, Ji ES (2022) Banxia-Houpu decoction diminishes iron toxicity damage in heart induced by chronic intermittent hypoxia. Pharm Biol 60:609–620. https://doi.org/10.1080/13880209.2022.2043392CrossRefPubMedPubMedCentral

53.

Pai P, Lai CJ, Lin CY, Liou YF, Huang CY, Lee SD (1985) (2016) Effect of superoxide anion scavenger on rat hearts with chronic intermittent hypoxia. J Appl Physiol 120:982–990. https://doi.org/10.1152/japplphysiol.01109.2014CrossRef

54.

Mo WL, Chai CZ, Kou JP, Yan YQ, Yu BY (2015) Sheng-Mai-San attenuates contractile dysfunction and structural damage induced by chronic intermittent hypoxia in mice. Chin J Nat Med 13:743–750. https://doi.org/10.1016/S1875-5364(15)30074-1CrossRefPubMed

55.

Diaz-Garcia E, Garcia-Tovar S, Alfaro E, Jaureguizar A, Casitas R, Sanchez-Sanchez B, Zamarron E, Fernandez-Lahera J, Lopez-Collazo E, Cubillos-Zapata C et al (2022) Inflammasome activation: a keystone of proinflammatory response in obstructive sleep apnea. Am J Respir Crit Care Med 205:1337–1348. https://doi.org/10.1164/rccm.202106-1445OCCrossRefPubMed

56.

Kohler M, Stradling JR (2010) Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 7:677–685. https://doi.org/10.1038/nrcardio.2010.145CrossRefPubMed

57.

Xiao F, Li X, Wang J, Cao J (2019) Mechanisms of vascular endothelial cell injury in response to intermittent and/or continuous hypoxia exposure and protective effects of anti-inflammatory and anti-oxidant agents. Sleep Breath 23:515–522. https://doi.org/10.1007/s11325-019-01803-9CrossRefPubMed

58.

Khalyfa A, Marin JM, Qiao Z, Rubio DS, Kheirandish-Gozal L, Gozal D (2020) Plasma exosomes in OSA patients promote endothelial senescence: effect of long-term adherent continuous positive airway pressure. Sleep 43. https://doi.org/10.1093/sleep/zsz217

59.

Zhang GH, Yu FC, Li Y, Wei Q, Song SS, Zhou FP, Tong JY (2017) Prolyl 4-hydroxylase domain protein 3 overexpression improved obstructive sleep apnea-induced cardiac perivascular fibrosis partially by suppressing endothelial-to-mesenchymal transition. J Am Heart Assoc 6. https://doi.org/10.1161/JAHA.117.006680

60.

Li MM, Zheng YL, Wang WD, Lin S, Lin HL (2021) Neuropeptide Y: an update on the mechanism underlying chronic intermittent hypoxia-induced endothelial dysfunction. Front Physiol 12:712281. https://doi.org/10.3389/fphys.2021.712281CrossRefPubMedPubMedCentral

61.

Sanz-Rubio D, Khalyfa A, Qiao Z, Ullate J, Marin JM, Kheirandish-Gozal L, Gozal D (2021) Cell-selective altered cargo properties of extracellular vesicles following in vitro exposures to intermittent hypoxia. Int J Mol Sci:22. https://doi.org/10.3390/ijms22115604

62.

Li Y, Zhang H, Du Y, Peng L, Qin Y, Liu H, Ma X, Wei Y (2021) Extracellular vesicle microRNA cargoes from intermittent hypoxia-exposed cardiomyocytes and their effect on endothelium. Biochem Biophys Res Commun 548:182–188. https://doi.org/10.1016/j.bbrc.2021.02.034CrossRefPubMed

63.

Kyotani Y, Takasawa S, Yoshizumi M (2019) Proliferative pathways of vascular smooth muscle cells in response to intermittent hypoxia. Int J Mol Sci 20. https://doi.org/10.3390/ijms20112706

64.

Kyotani Y, Itaya-Hironaka A, Yamauchi A, Sakuramoto-Tsuchida S, Makino M, Takasawa S, Yoshizumi M (2018) Intermittent hypoxia-induced epiregulin expression by IL-6 production in human coronary artery smooth muscle cells. FEBS Open Bio 8:868–876. https://doi.org/10.1002/2211-5463.12430CrossRefPubMedPubMedCentral

65.

Rakusan K, Chvojkova Z, Oliviero P, Ostadalova I, Kolar F, Chassagne C, Samuel JL, Ostadal B (2007) ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats. Am J Physiol Heart Circ Physiol 292:H1237–H1244. https://doi.org/10.1152/ajpheart.00965.2006CrossRefPubMed

66.

Hu K, Deng W, Yang J, Wei Y, Wen C, Li X, Chen Q, Ke D, Li G (2020) Intermittent hypoxia reduces infarct size in rats with acute myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord 20:422. https://doi.org/10.1186/s12872-020-01702-yCrossRefPubMedPubMedCentral

67.

Lavie L (2015) Oxidative stress in obstructive sleep apnea and intermittent hypoxia--revisited--the bad ugly and good: implications to the heart and brain. Sleep Med Rev 20:27–45. https://doi.org/10.1016/j.smrv.2014.07.003CrossRefPubMed

68.

Park AM, Nagase H, Kumar SV, Suzuki YJ (2007) Effects of intermittent hypoxia on the heart. Antioxid Redox Signal 9:723–729. https://doi.org/10.1089/ars.2007.1460CrossRefPubMed

69.

Belaidi E, Khouri C, Harki O, Baillieul S, Faury G, Briancon-Marjollet A, Pepin JL, Arnaud C (2022) Cardiac consequences of intermittent hypoxia: a matter of dose? A systematic review and meta-analysis in rodents. Eur Respir Rev 31. https://doi.org/10.1183/16000617.0269-2021

70.

Zhao X, Li X, Xu H, Qian Y, Fang F, Yi H, Guan J, Yin SK (2019) Relationships between cardiometabolic disorders and obstructive sleep apnea: implications for cardiovascular disease risk. J Clin Hypertens (Greenwich) 21:280–290. https://doi.org/10.1111/jch.13473CrossRefPubMed

71.

Zhang X, Wang S, Xu H, Yi H, Guan J, Yin S (2021) Metabolomics and microbiome profiling as biomarkers in obstructive sleep apnoea: a comprehensive review. Eur Respir Rev 30. https://doi.org/10.1183/16000617.0220-2020

72.

Ferrarini A, Ruperez FJ, Erazo M, Martinez MP, Villar-Alvarez F, Peces-Barba G, Gonzalez-Mangado N, Troncoso MF, Ruiz-Cabello J, Barbas C (2013) Fingerprinting-based metabolomic approach with LC-MS to sleep apnea and hypopnea syndrome: a pilot study. Electrophoresis 34:2873–2881. https://doi.org/10.1002/elps.201300081CrossRefPubMed

73.

Lebkuchen A, Carvalho VM, Venturini G, Salgueiro JS, Freitas LS, Dellavance A, Martins FC, Lorenzi-Filho G, Cardozo KHM, Drager LF (2018) Metabolomic and lipidomic profile in men with obstructive sleep apnoea: implications for diagnosis and biomarkers of cardiovascular risk. Sci Rep 8:11270. https://doi.org/10.1038/s41598-018-29727-6CrossRefPubMedPubMedCentral

74.

Deng M, Huang YT, Xu JQ, Ke X, Dong YF, Cheng XS (2020) Association between intermittent hypoxia and left ventricular remodeling in patients with obstructive sleep apnea-hypopnea syndrome. Front Physiol 11:608347. https://doi.org/10.3389/fphys.2020.608347CrossRefPubMed

75.

Oliveira W, Campos O, Bezerra Lira-Filho E, Cintra FD, Vieira M, Ponchirolli A, de Paola A, Tufik S, Poyares D (2008) Left atrial volume and function in patients with obstructive sleep apnea assessed by real-time three-dimensional echocardiography. J Am Soc Echocardiogr 21:1355–1361. https://doi.org/10.1016/j.echo.2008.09.007CrossRefPubMed

76.

Hayashi T, Yamashita C, Matsumoto C, Kwak CJ, Fujii K, Hirata T, Miyamura M, Mori T, Ukimura A, Okada Y et al (2008) Role of gp91phox-containing NADPH oxidase in left ventricular remodeling induced by intermittent hypoxic stress. Am J Physiol Heart Circ Physiol 294:H2197–H2203. https://doi.org/10.1152/ajpheart.91496.2007CrossRefPubMed

77.

Chen L, Einbinder E, Zhang Q, Hasday J, Balke CW, Scharf SM (2005) Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. Am J Respir Crit Care Med 172:915–920. https://doi.org/10.1164/rccm.200504-560OCCrossRefPubMed

78.

Daubert MA, Whellan DJ, Woehrle H, Tasissa G, Anstrom KJ, Lindenfeld J, Benjafield A, Blase A, Punjabi N, Fiuzat M et al (2018) Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial. Am Heart J 201:40–48. https://doi.org/10.1016/j.ahj.2018.03.026CrossRefPubMed

79.

Wang W, Gu H, Li W, Lin Y, Yao X, Luo W, Lu F, Huang S, Shi Y, Huang Z (2021) SRC-3 knockout attenuates myocardial injury induced by chronic intermittent hypoxia in mice. Oxid Med Cell Longev 2021:6372430. https://doi.org/10.1155/2021/6372430CrossRefPubMedPubMedCentral

80.

Farre N, Otero J, Falcones B, Torres M, Jorba I, Gozal D, Almendros I, Farre R, Navajas D (2018) Intermittent hypoxia mimicking sleep apnea increases passive stiffness of myocardial extracellular matrix. A multiscale study. Front Physiol 9:1143. https://doi.org/10.3389/fphys.2018.01143CrossRefPubMedPubMedCentral

81.

Zhou W, Li S, Wan N, Zhang Z, Guo R, Chen B (2012) Effects of various degrees of oxidative stress induced by intermittent hypoxia in rat myocardial tissues. Respirology 17:821–829. https://doi.org/10.1111/j.1440-1843.2012.02157.xCrossRefPubMed

82.

Inamoto S, Yoshioka T, Yamashita C, Miyamura M, Mori T, Ukimura A, Matsumoto C, Matsumura Y, Kitaura Y, Hayashi T (2010) Pitavastatin reduces oxidative stress and attenuates intermittent hypoxia-induced left ventricular remodeling in lean mice. Hypertens Res 33:579–586. https://doi.org/10.1038/hr.2010.36CrossRefPubMed

83.

Nishioka S, Yoshioka T, Nomura A, Kato R, Miyamura M, Okada Y, Ishizaka N, Matsumura Y, Hayashi T (2013) Celiprolol reduces oxidative stress and attenuates left ventricular remodeling induced by hypoxic stress in mice. Hypertens Res 36:934–939. https://doi.org/10.1038/hr.2013.60CrossRefPubMed

84.

Williams AL, Chen L, Scharf SM (2010) Effects of allopurinol on cardiac function and oxidant stress in chronic intermittent hypoxia. Sleep Breath 14:51–57. https://doi.org/10.1007/s11325-009-0279-xCrossRefPubMed

85.

Imano H, Kato R, Tanikawa S, Yoshimura F, Nomura A, Ijiri Y, Yamaguchi T, Izumi Y, Yoshiyama M, Hayashi T (2018) Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia. J Pharmacol Sci 137:274–282. https://doi.org/10.1016/j.jphs.2018.07.002CrossRefPubMed

86.

Force USPST, Mangione CM, Barry MJ, Nicholson WK, Cabana M, Chelmow D, Rucker Coker T, Davidson KW, Davis EM, Donahue KE et al (2022) Screening for obstructive sleep apnea in adults: US preventive services task force recommendation statement. JAMA 328:1945–1950. https://doi.org/10.1001/jama.2022.20304CrossRef

87.

Lui MM, Tse HF, Lam DC, Lau KK, Chan CW, Ip MS (2021) Continuous positive airway pressure improves blood pressure and serum cardiovascular biomarkers in obstructive sleep apnoea and hypertension. Eur Respir J 58. https://doi.org/10.1183/13993003.03687-2020

88.

Yu J, Zhou Z, McEvoy RD, Anderson CS, Rodgers A, Perkovic V, Neal B (2017) Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea: a systematic review and meta-analysis. JAMA 318:156–166. https://doi.org/10.1001/jama.2017.7967CrossRefPubMedPubMedCentral

89.

Heinzer R, Eckert D (2020) Treatment for obstructive sleep apnoea and cardiovascular diseases: are we aiming at the wrong target? Lancet Respir Med 8:323–325. https://doi.org/10.1016/S2213-2600(19)30351-0CrossRefPubMed

90.

Ng SSS, Chan RSM, Woo J, Chan TO, Cheung BHK, Sea MMM, To KW, Chan KKP, Ngai J, Yip WH et al (2015) A randomized controlled study to examine the effect of a lifestyle modification program in OSA. Chest 148:1193–1203. https://doi.org/10.1378/chest.14-3016CrossRefPubMed

91.

Gautier-Veyret E, Pepin JL, Stanke-Labesque F (2018) Which place of pharmacological approaches beyond continuous positive airway pressure to treat vascular disease related to obstructive sleep apnea? Pharmacol Ther 186:45–59. https://doi.org/10.1016/j.pharmthera.2017.12.006CrossRefPubMed

Titel: Effects of obstructive sleep apnea on myocardial injury and dysfunction: a review focused on the molecular mechanisms of intermittent hypoxia
verfasst von: Wen Liu
Qing Zhu
Xinxin Li
Yonghuai Wang
Cuiting Zhao
Chunyan Ma
Publikationsdatum: 07.08.2023
Verlag: Springer International Publishing
Erschienen in: Sleep and Breathing / Ausgabe 1/2024
Print ISSN: 1520-9512
Elektronische ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-023-02893-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Effects of obstructive sleep apnea on myocardial injury and dysfunction: a review focused on the molecular mechanisms of intermittent hypoxia

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Diurnal variation in variables related to cognitive performance: a systematic review

Analysis by sex of safety and effectiveness of transvenous phrenic nerve stimulation

Prevalence, associated risk factors, and respiratory event distribution of obstructive sleep apnea in children with Down syndrome

On the link between rapid eye movement sleep and yawning

Effects of different Chinese traditional exercises on sleep quality and mental health of adults: systematic review and meta-analysis

Fine particulate matter and sleep-disordered breathing severity in a large Italian cohort

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin